| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.10▼ | 2.11▼ | 2.10▼ | 2.25▼ | 1.98▲ |
| MA10 | 2.10▼ | 2.10▼ | 2.13▼ | 2.10▼ | 2.34▼ |
| MA20 | 2.10▼ | 2.15▼ | 2.20▼ | 1.94▲ | 3.27▼ |
| MA50 | 2.10▼ | 2.22▼ | 2.20▼ | 2.55▼ | 6.72▼ |
| MA100 | 2.13▼ | 2.17▼ | 2.00▲ | 3.62▼ | 7.60▼ |
| MA200 | 2.20▼ | 1.98▲ | 2.01▲ | 6.36▼ | 10.04▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | -0.001▼ | -0.020▼ | 0.094▲ | 0.079▲ |
| RSI | 35.073▼ | 36.797▼ | 37.221▼ | 46.323▼ | 31.052▼ |
| STOCH | 52.381 | 62.346 | 27.298 | 73.465 | 13.758▼ |
| WILL %R | -100.000▼ | -79.167▼ | -82.759▼ | -50.327 | -79.945▼ |
| CCI | -141.573▼ | -40.936 | -70.735 | 32.759 | -56.992 |
|
Saturday, June 14, 2025 05:49 AM
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both ...
|
|
Saturday, June 14, 2025 05:12 AM
Iovance faces major setbacks with AMTAGVI's weak launch, cash burn, and scalability issues despite scientific progress. Find out why IOVA stock is a sell.
|
|
Monday, June 09, 2025 05:00 PM
SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 16/06/25 | 2.20 | 2.22 | 2.011 | 2.08 | 12,600,557 |
| 13/06/25 | 2.23 | 2.31 | 2.20 | 2.24 | 8,786,100 |
| 12/06/25 | 2.20 | 2.32 | 2.15 | 2.31 | 13,544,000 |
| 11/06/25 | 2.42 | 2.43 | 2.21 | 2.24 | 17,192,800 |
| 10/06/25 | 2.205 | 2.465 | 2.205 | 2.395 | 20,109,230 |
| 09/06/25 | 2.18 | 2.30 | 2.14 | 2.21 | 18,236,515 |
| 06/06/25 | 1.81 | 2.05 | 1.81 | 2.05 | 20,578,200 |
| 05/06/25 | 1.84 | 1.86 | 1.77 | 1.80 | 6,827,000 |
| 04/06/25 | 1.81 | 1.87 | 1.80 | 1.83 | 5,715,200 |
| 03/06/25 | 1.75 | 1.85 | 1.705 | 1.82 | 9,670,991 |
|
|
||||
|
|
||||
|
|